Development asset linked to Xinhua Hospital, Shanghai in public FDA and regional records.
pharma · Levodopa-Induced Dyskinesia
Xinhua Hospital, Shanghai
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Xinhua Hospital, Shanghai drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
CN HQ
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Programs
- 1
- Drugs
- 3
- Patents
- 0
Xinhua Hospital, Shanghai pipeline
Portfolio lens on 3 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Xinhua Hospital, Shanghai drug portfolio — 3 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
levodopa
Nervous system (N04)US regulatory status: approved. Molecular target: D(3) dopamine receptor.
- Target
- D(3) dopamine receptor
- Mechanism
- Dopamine D3 receptor agonist
-
Development asset linked to Xinhua Hospital, Shanghai in public FDA and regional records.